RenovoRx Statistics
Total Valuation
RenovoRx has a market cap or net worth of $29.74 million. The enterprise value is $18.98 million.
| Market Cap | 29.74M |
| Enterprise Value | 18.98M |
Important Dates
The last earnings date was Wednesday, November 13, 2024, before market open.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
RenovoRx has 23.99 million shares outstanding. The number of shares has increased by 88.79% in one year.
| Current Share Class | 23.99M |
| Shares Outstanding | 23.99M |
| Shares Change (YoY) | +88.79% |
| Shares Change (QoQ) | +3.71% |
| Owned by Insiders (%) | 1.90% |
| Owned by Institutions (%) | 7.88% |
| Float | 23.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.04 |
| P/TBV Ratio | 3.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.66
| Current Ratio | 5.66 |
| Quick Ratio | 5.40 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -258.95% and return on invested capital (ROIC) is -178.66%.
| Return on Equity (ROE) | -258.95% |
| Return on Assets (ROA) | -93.31% |
| Return on Capital (ROIC) | -178.66% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.15M |
| Employee Count | 8 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +103.61% in the last 52 weeks. The beta is 0.99, so RenovoRx's price volatility has been similar to the market average.
| Beta (5Y) | 0.99 |
| 52-Week Price Change | +103.61% |
| 50-Day Moving Average | 1.04 |
| 200-Day Moving Average | 1.21 |
| Relative Strength Index (RSI) | 70.26 |
| Average Volume (20 Days) | 42,641 |
Short Selling Information
The latest short interest is 71,850, so 0.30% of the outstanding shares have been sold short.
| Short Interest | 71,850 |
| Short Previous Month | 91,861 |
| Short % of Shares Out | 0.30% |
| Short % of Float | 0.31% |
| Short Ratio (days to cover) | 3.43 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -10.12M |
| Pretax Income | -8.05M |
| Net Income | -9.16M |
| EBITDA | n/a |
| EBIT | -10.12M |
| Earnings Per Share (EPS) | -$0.49 |
Balance Sheet
| Cash & Cash Equivalents | 9.56M |
| Total Debt | n/a |
| Net Cash | 9.56M |
| Net Cash Per Share | $0.40 |
| Equity (Book Value) | 7.07M |
| Book Value Per Share | 0.29 |
| Working Capital | 8.26M |
Cash Flow
| Operating Cash Flow | -8.75M |
| Capital Expenditures | n/a |
| Free Cash Flow | -8.75M |
| FCF Per Share | -$0.36 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RenovoRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -88.79% |
| Shareholder Yield | -88.79% |
| Earnings Yield | -32.91% |
| FCF Yield | -31.42% |
Analyst Forecast
The average price target for RenovoRx is $6.13, which is 394.36% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.13 |
| Price Target Difference | 394.36% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |